Last 34 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -6.19 | — | — | 46.89 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 10.33 | 19.39 | 13.93 | 1.35 | 6.90 | 13.13 | 7.28 | 8.89 | 2.81 | 11.55 | 10.46 | 12.82 | 13.32 |
| — | +47.7% | +91.3% | -84.8% | +145.8% | +13.6% | -30.4% | -30.6% | -78.9% | +3.6% | -26.9% | -23.9% | -57.3% | |
| P/B Ratio | 3.47 | 4.06 | 3.32 | 1.58 | 1.45 | 2.82 | 2.47 | 2.18 | 2.30 | 3.10 | 2.58 | 2.63 | 2.22 |
| — | +44.1% | +34.3% | -27.7% | -36.8% | -9.2% | -3.9% | -16.8% | +3.7% | +35.7% | -4.8% | +7.9% | -21.3% | |
| P/FCF | — | — | — | — | — | — | 13.98 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 2.53 | — | 90.99 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Arcus Biosciences, Inc.'s operating margin was -345.5% in Q4 2025, up 200.7 pp QoQ and up 50.7 pp YoY. The trailing four-quarter average of -333.1% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 742.4% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | -642.4% | 92.3% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | -742.4% | -7.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin | -156.3% | -345.5% | -546.2% | -5.0% | -435.7% | -396.2% | -218.8% | -271.8% | -11.0% | -293.5% | -250.0% | -286.2% | -344.0% |
| — | +12.8% | -149.7% | +98.2% | -3848.7% | -35.0% | +12.5% | +5.0% | +96.8% | -32.7% | -17.9% | -12.0% | +7.6% | |
| Net Margin | -142.9% | -297.0% | -519.2% | -5.0% | -400.0% | -361.5% | -191.7% | -238.5% | -2.8% | -261.3% | -221.9% | -258.6% | -320.0% |
| — | +17.9% | -170.9% | +97.9% | -14400.1% | -38.4% | +13.6% | +7.8% | +99.1% | -30.4% | -12.6% | -4.2% | +15.3% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -63.3% | -18.4% | -27.4% | -1.5% | -22.0% | -17.9% | -15.3% | -13.9% | -0.7% | -16.5% | -13.1% | -12.9% | -12.7% |
| — | -2.6% | -78.8% | +89.3% | -3121.9% | -8.5% | -17.3% | -7.7% | +94.6% | -65.8% | -45.4% | -48.2% | -53.3% | |
| ROA | -30.8% | -9.3% | -13.2% | -0.7% | -9.7% | -7.8% | -7.5% | -7.5% | -0.3% | -7.1% | -5.9% | -6.1% | -6.2% |
| — | -18.5% | -74.6% | +90.4% | -2799.6% | -10.4% | -28.1% | -23.7% | +94.6% | -43.9% | -30.1% | -36.7% | -41.9% | |
| ROIC | -64.1% | -20.9% | -29.6% | -1.5% | -23.0% | -18.9% | -17.3% | -15.5% | -2.7% | -19.8% | -17.6% | -17.8% | -13.8% |
| — | -10.7% | -71.5% | +90.5% | -744.1% | +4.3% | +2.0% | +12.9% | +80.3% | -107.2% | -100.8% | -65.2% | -62.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.16 | 0.16 | 0.25 | 0.20 | 0.11 | 0.12 | 0.10 | 0.02 | 0.02 | 0.02 | 0.02 | — | — |
| — | +26.8% | +148.0% | +1046.1% | +626.2% | +419.6% | +493.1% | — | — | -87.0% | -89.9% | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.36 | 4.36 | 3.65 | 4.50 | 5.37 | 4.50 | 5.24 | 5.14 | 5.22 | 4.52 | 4.41 | 5.47 | 5.66 |
| — | -3.0% | -30.4% | -12.3% | +3.0% | -0.5% | +19.0% | -6.2% | -7.9% | -18.2% | -29.1% | -26.9% | -27.7% | |
| Quick Ratio | 4.36 | 4.36 | 3.65 | 4.50 | 5.37 | 4.50 | 5.24 | 5.14 | 5.22 | 4.52 | 4.41 | 5.47 | 5.66 |
| — | -3.0% | -30.4% | -12.3% | +3.0% | -0.5% | +19.0% | -6.2% | -7.9% | -18.2% | -29.1% | -26.9% | -27.7% | |
| Interest Coverage | — | — | -47.33 | -4.00 | -122.00 | -51.50 | -105.00 | — | -16.00 | — | -80.00 | — | -86.00 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 34 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonArcus Biosciences, Inc.'s current P/E is -6.2x. The average P/E over the last 1 quarters is 46.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Arcus Biosciences, Inc.'s current operating margin is -156.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Arcus Biosciences, Inc.'s business trajectory between earnings reports.